Tresiba and Sleep: How Insulin Degludec Affects Your Rest and What You Can Do About It

The direct answer

Tresiba does not cause insomnia as a pharmacologic side effect. What disrupts sleep in people on basal insulin is glucose instability overnight, most commonly nocturnal hypoglycemia (waking with sweating, headache, or confusion) or hyperglycemia (waking to urinate or drink). Insulin degludec's molecular design, described in its FDA label, produces a slower and flatter absorption curve than older basal insulins such as insulin glargine U100, which is the pharmacologic reason clinicians expect fewer nighttime glucose swings on Tresiba. Whether that translates into a measurable improvement in subjective sleep quality, as opposed to fewer hypoglycemic awakenings, has not been established with the evidence available for this article, and readers should not treat any single percentage reduction in nocturnal hypoglycemia as a guarantee of their own experience.

Why sleep and basal insulin are connected at all

People with diabetes on any basal insulin regimen commonly report disrupted rest, and the relationship runs in both directions. Poor sleep raises stress hormones and next-day insulin resistance, making glucose control harder, which in turn can produce more overnight excursions and more disrupted sleep. This feedback loop is a recognized concern in diabetes care, though the exact prevalence figures for insulin-treated patients vary across studies and should be checked against a current source before being quoted as a fixed statistic.

Independent of any insulin, type 2 diabetes is associated with a higher prevalence of obstructive sleep apnea, restless legs syndrome, and nocturia. Distinguishing insulin-related sleep disruption from disease-related or comorbidity-related sleep disruption requires looking at the pattern: does the disruption track with low or high overnight glucose readings on a CGM, or does it happen even on nights with a stable glucose profile? That distinction determines whether the fix is a dose or timing change, or a referral for a sleep evaluation.

How Tresiba's pharmacokinetics relate to overnight glucose

Insulin degludec forms multi-hexamer chains after subcutaneous injection, creating a slow-release depot under the skin. The FDA label describes a duration of action exceeding 42 hours, which is roughly double the labeled duration of insulin glargine U100 (Lantus). Insulin glargine U100 has a modest absorption peak several hours after injection; if dosed at bedtime, that peak can coincide with the early-morning rise in hepatic glucose output driven by cortisol (the "dawn phenomenon"), which can produce less predictable overnight glucose behavior. Insulin degludec's profile is described as comparatively flat and steady at steady state.

This mechanistic difference is the basis for the expectation that degludec produces fewer overnight glucose swings than glargine U100. Randomized trials comparing the two insulins, including the SWITCH 1 and SWITCH 2 crossover trials in type 1 and type 2 diabetes, reported lower rates of nocturnal hypoglycemia with degludec. The exact effect sizes, confidence intervals, and patient counts from those trials are not reproduced here because they could not be verified against a confirmed primary source for this draft; an editor with direct access to the published SWITCH 1 and SWITCH 2 papers should confirm the numbers before they are published as precise figures.

Evidence-status interaction assessment: Tresiba and sleep

Injection timing: what is flexible and what is not

The FDA label for Tresiba permits dosing at any time of day, provided at least 8 hours separate consecutive doses. This flexibility is a labeled feature, not an off-label workaround, and it is the basis for three common timing strategies:

Evening dosing (roughly 8 PM to 10 PM). This is the default many clinicians use for basal insulins, placing the slow absorption phase across the overnight period.

Morning dosing. Because degludec's action extends well past 24 hours, a morning injection can still provide adequate overnight basal coverage. Patients who find bedtime injections anxiety-provoking, or who have practical reasons to prefer morning dosing, have a labeled option to do so, though any timing change should be paired with closer fasting-glucose monitoring during the transition.

Variable timing for shift workers or irregular schedules. The degludec flexible-dosing trial design (BEGIN FLEX) tested a schedule alternating shorter and longer intervals between doses and found glycemic control was not compromised, within the minimum 8-hour spacing rule. This is relevant for nurses, pilots, and others whose sleep windows shift, but the specific hypoglycemia and HbA1c numbers from that trial should be confirmed against the primary publication rather than repeated from memory.

Nocturnal hypoglycemia: recognizing it, preventing it, responding to it

Even with a comparatively flat PK profile, nocturnal hypoglycemia can still occur on Tresiba, most often from dose titration that outpaces need, a skipped or delayed meal, unusual exercise, or alcohol.

Symptoms are often muted during sleep. Classic hypoglycemia symptoms like tremor and palpitations may not be enough to wake someone. More common overnight signs are waking with a headache, damp sheets, or unexplained fatigue the next morning; a bed partner may notice restlessness or unusual movement. This is a recognized limitation of relying on symptoms alone, and it is the practical argument for CGM with an audible low-glucose alert rather than symptom-based detection alone.

Prevention strategies that are reasonable to discuss with a prescriber:

1. A bedtime snack containing both carbohydrate and protein has been studied as a way to reduce nocturnal hypoglycemia frequency in basal-bolus regimens. Whether a snack is needed depends on the individual's overnight CGM pattern; it is not a universal requirement.
2. CGM with a personalized (rather than default) low-glucose alert threshold is recommended for patients with reduced hypoglycemia awareness, consistent with general CGM practice guidance.
3. Conservative dose titration, adjusting basal insulin in small increments based on fasting glucose trends rather than large jumps, is the most common correctable cause of preventable nocturnal lows.

If a nocturnal low wakes you: the standard approach is 15 grams of fast-acting carbohydrate (for example, glucose tablets or juice), waiting about 15 minutes, and rechecking before eating more. Overtreating a low can cause a rebound high that itself disrupts sleep through increased urination and thirst. Keeping fast-acting carbohydrate within reach of the bed avoids a fully-awake trip to the kitchen.

This is general guidance, not an individualized dosing instruction. Anyone titrating insulin or adjusting a bedtime snack routine should do so with their prescriber or diabetes care team, particularly during any dose change.

Sleep hygiene considerations specific to basal insulin

Pre-bed glucose target. Going to bed with glucose in a moderate range (commonly cited as roughly 100 to 180 mg/dL, though individualized targets vary) is generally associated with a more stable overnight CGM trace than going to bed very low or very high. Below that range, nocturnal hypoglycemia risk rises; well above it, osmotic symptoms such as thirst and urination can fragment sleep.

Alcohol and late meals. Alcohol suppresses the liver's glucose output for several hours after consumption, which can compound the risk of a nocturnal low when combined with basal insulin coverage. Pairing alcohol with a carbohydrate-containing meal and setting a slightly higher CGM low alert on drinking nights is a reasonable precaution. Late, high-fat meals can delay gastric emptying and cause glucose effects that carry into the early sleep period; finishing the last meal two to three hours before bed is a common recommendation, though this is general dietary guidance rather than a Tresiba-specific finding.

Insulin storage and temperature. According to the FDA label, an in-use Tresiba pen is stable at room temperature (below 86°F/30°C) for a defined number of weeks; check the current label for the exact in-use duration, since labeling details can be updated. Injecting cold insulin directly from the refrigerator can increase injection-site discomfort. A cool bedroom is standard general sleep hygiene advice, not specific to insulin therapy.

Reading an overnight CGM trace

For CGM users, the overnight segment of the ambulatory glucose profile is one of the more actionable pieces of data for basal insulin adjustment, because it isolates the effect of the basal dose from meal-related swings.

A stable overnight trace generally stays within a moderate range with low variability and a relatively flat line. A gradual rise of 20 to 30 mg/dL toward morning is consistent with a normal dawn phenomenon and may not need intervention unless fasting glucose is persistently elevated.

Patterns worth discussing with a prescriber include repeated dips into hypoglycemic range in the middle of the night (suggesting the basal dose may be too high for current needs), a sharp rise starting in the early morning hours (suggesting an exaggerated dawn phenomenon that may call for a dose adjustment or an added daytime therapy), and high overnight glucose variability, which several CGM consensus statements associate with greater hypoglycemia risk. Because the specific variability thresholds cited in different consensus documents vary by year and organization, the current version of the relevant guideline should be checked rather than relying on a single remembered cutoff.

Tresiba compared with other basal insulins, for sleep specifically

Versus insulin glargine U100 (Lantus, Basaglar). Head-to-head trials in the degludec development program reported lower nocturnal hypoglycemia rates for degludec. This is the strongest evidence base among the comparisons discussed here, though again, the exact percentage reductions should be confirmed against the primary trial publications before being restated as a precise figure.

Versus insulin glargine U300 (Toujeo). Glargine U300 is also formulated to have a flatter profile than U100 glargine. A head-to-head trial (BRIGHT) in insulin-naive patients with type 2 diabetes reported similar overall hypoglycemia and glycemic outcomes between the two ultra-long or long-acting analogs at 24 weeks. For someone already stable on Toujeo without nighttime lows, there is no established basis in the evidence reviewed here for expecting a meaningful additional sleep benefit from switching to Tresiba.

Versus NPH insulin. NPH has a pronounced peak several hours after injection, and bedtime NPH dosing is well recognized as carrying a higher nocturnal hypoglycemia risk than the newer basal analogs, including degludec. Anyone still using NPH who reports poor sleep has a reasonable case for discussing a switch to a peakless or flatter basal analog with their prescriber.

When sleep problems persist despite stable glucose

If overnight CGM data looks stable and sleep still suffers, the cause is likely outside insulin dosing. The most common comorbid contributors in people with diabetes are obstructive sleep apnea (suspected with snoring, witnessed pauses in breathing, or daytime sleepiness despite adequate time in bed), restless legs syndrome (worth an iron/ferritin check, since iron deficiency is a treatable contributor and is common in diabetes), and nocturia unrelated to glucose, which can stem from autonomic neuropathy affecting the bladder. These require their own diagnostic workup (a home sleep apnea test or polysomnography, iron studies, or a bladder diary) rather than another insulin dose adjustment.

Practical checklist for discussion with your care team

• Check pre-bed glucose and discuss an individualized target range with your prescriber
• Set a CGM low-glucose alert threshold appropriate to your hypoglycemia awareness, in consultation with your care team
• Keep fast-acting glucose within reach of the bed
• Use a consistent injection time that fits your schedule, respecting the minimum 8-hour interval between doses if you change timing
• Discuss alcohol timing and a possible bedtime snack with your prescriber if you notice a pattern of nighttime lows
• Review overnight CGM data periodically with your provider or diabetes educator
• Ask about screening for obstructive sleep apnea if you snore, gasp, or feel excessively sleepy during the day despite adequate glucose control and adequate time in bed
• If you use the U200 pen, confirm you are reading the correct unit dose, since U100 and U200 deliver different amounts of insulin per unit of pen movement

This checklist is a starting point for a conversation with your prescriber or pharmacist, not a substitute for individualized dosing instructions.

What is established, what is plausible, and what is not established

Established: Tresiba (insulin degludec) has an FDA-labeled duration of action exceeding 42 hours and a flatter absorption profile than insulin glargine U100. It carries a labeled allowance for flexible dosing timing with a minimum 8-hour interval. Head-to-head trials in its development program reported lower nocturnal hypoglycemia rates compared with glargine U100.

Plausible but unproven from the material reviewed here: That this pharmacokinetic advantage translates into a measurable, patient-reported improvement in sleep quality specifically, as distinct from a reduction in nocturnal hypoglycemia events. That a particular injection time (morning versus evening) changes sleep outcomes for a given individual; label flexibility supports either, but individual response varies.

Not established: Any precise numeric reduction in nocturnal hypoglycemia or sleep disruption attributable to Tresiba versus a comparator, at the level of exact percentages, without verification against the primary trial publication. Any direct pharmacologic interaction between insulin degludec and common sleep medications.